只使用免费官方源：SEC Forms 3/4/5 结构化内部人申报，以及 FINRA Consolidated NMS 场外卖空成交量。 两类数据均保留来源边界，不转写成买卖建议。
SEC 已完成季度 Forms 3/4/5 结构化历史基线 + EDGAR 当前季度 Form 4 增量；个股卡片仅展示当前自然季度的非衍生证券买卖代码 P/S（公开市场或私下交易），成交金额由股数 × 每股价格计算。
官方数据说明| 交易日 / 申报日 | 公司 | 申报人 | 类型 | 股数 | 每股价格 | 派生金额 | 持有后股数 | 原始申报 |
|---|---|---|---|---|---|---|---|---|
| 2026-07-31 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 24,944 | US$9.93 | US$247,693.92 | 17,329,570 | SEC |
| 2026-07-31 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 24,944 | US$9.93 | US$247,693.92 | 17,329,570 | SEC |
| 2026-07-31 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 24,944 | US$9.93 | US$247,693.92 | 17,329,570 | SEC |
| 2026-07-31 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 24,944 | US$9.93 | US$247,693.92 | 17,329,570 | SEC |
| 2026-07-31 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 24,944 | US$9.93 | US$247,693.92 | 17,329,570 | SEC |
| 2026-07-31 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 24,944 | US$9.93 | US$247,693.92 | 17,329,570 | SEC |
| 2026-07-29 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 20,824 | US$9.99 | US$208,031.76 | 17,304,626 | SEC |
| 2026-07-29 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 20,824 | US$9.99 | US$208,031.76 | 17,304,626 | SEC |
| 2026-07-29 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 20,824 | US$9.99 | US$208,031.76 | 17,304,626 | SEC |
| 2026-07-29 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 20,824 | US$9.99 | US$208,031.76 | 17,304,626 | SEC |
| 2026-07-29 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 20,824 | US$9.99 | US$208,031.76 | 17,304,626 | SEC |
| 2026-07-29 2026-07-31 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 20,824 | US$9.99 | US$208,031.76 | 17,304,626 | SEC |
| 2026-07-24 2026-07-28 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 41,319 | US$9.99 | US$412,776.81 | 17,283,802 | SEC |
| 2026-07-24 2026-07-28 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 41,319 | US$9.99 | US$412,776.81 | 17,283,802 | SEC |
| 2026-07-24 2026-07-28 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 41,319 | US$9.99 | US$412,776.81 | 17,283,802 | SEC |
| 2026-07-24 2026-07-28 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 41,319 | US$9.99 | US$412,776.81 | 17,283,802 | SEC |
| 2026-07-24 2026-07-28 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 41,319 | US$9.99 | US$412,776.81 | 17,283,802 | SEC |
| 2026-07-24 2026-07-28 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 41,319 | US$9.99 | US$412,776.81 | 17,283,802 | SEC |
| 2026-07-23 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 59,880 | US$9.96 | US$596,404.80 | 17,242,483 | SEC |
| 2026-07-23 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 59,880 | US$9.96 | US$596,404.80 | 17,242,483 | SEC |
| 2026-07-23 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 59,880 | US$9.96 | US$596,404.80 | 17,242,483 | SEC |
| 2026-07-23 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 59,880 | US$9.96 | US$596,404.80 | 17,242,483 | SEC |
| 2026-07-23 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 59,880 | US$9.96 | US$596,404.80 | 17,242,483 | SEC |
| 2026-07-23 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 59,880 | US$9.96 | US$596,404.80 | 17,242,483 | SEC |
| 2026-07-22 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 84,124 | US$9.93 | US$835,351.32 | 17,182,603 | SEC |
| 2026-07-22 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 84,124 | US$9.93 | US$835,351.32 | 17,182,603 | SEC |
| 2026-07-22 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 84,124 | US$9.93 | US$835,351.32 | 17,182,603 | SEC |
| 2026-07-22 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 84,124 | US$9.93 | US$835,351.32 | 17,182,603 | SEC |
| 2026-07-22 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 84,124 | US$9.93 | US$835,351.32 | 17,182,603 | SEC |
| 2026-07-22 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 84,124 | US$9.93 | US$835,351.32 | 17,182,603 | SEC |
| 2026-07-21 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 120,582 | US$9.55 | US$115.16万 | 17,098,479 | SEC |
| 2026-07-21 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 120,582 | US$9.55 | US$115.16万 | 17,098,479 | SEC |
| 2026-07-21 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 120,582 | US$9.55 | US$115.16万 | 17,098,479 | SEC |
| 2026-07-21 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 120,582 | US$9.55 | US$115.16万 | 17,098,479 | SEC |
| 2026-07-21 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 120,582 | US$9.55 | US$115.16万 | 17,098,479 | SEC |
| 2026-07-21 2026-07-23 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 120,582 | US$9.55 | US$115.16万 | 17,098,479 | SEC |
| 2026-07-21 2026-07-23 | ADPT Adaptive Biotechnologies Corp | ROBINS HARLAN S Officer · Chief Scientific Officer | 卖出（S） | 278,698 | US$21.72 | US$605.33万 | 1,025,760 | SEC |
| 2026-07-21 2026-07-23 | ADPT Adaptive Biotechnologies Corp | ROBINS HARLAN S Officer · Chief Scientific Officer | 卖出（S） | 213,702 | US$22.12 | US$472.71万 | 812,058 | SEC |
| 2026-07-17 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 7,882 | US$8.95 | US$70,543.90 | 16,977,927 | SEC |
| 2026-07-17 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 7,882 | US$8.95 | US$70,543.90 | 16,977,927 | SEC |
| 2026-07-17 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 7,882 | US$8.95 | US$70,543.90 | 16,977,927 | SEC |
| 2026-07-17 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 7,882 | US$8.95 | US$70,543.90 | 16,977,927 | SEC |
| 2026-07-17 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 7,882 | US$8.95 | US$70,543.90 | 16,977,927 | SEC |
| 2026-07-17 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 7,882 | US$8.95 | US$70,543.90 | 16,977,927 | SEC |
| 2026-07-16 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 152,472 | US$8.93 | US$136.16万 | 16,970,045 | SEC |
| 2026-07-16 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 152,472 | US$8.93 | US$136.16万 | 16,970,045 | SEC |
| 2026-07-16 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 152,472 | US$8.93 | US$136.16万 | 16,970,045 | SEC |
| 2026-07-16 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 152,472 | US$8.93 | US$136.16万 | 16,970,045 | SEC |
| 2026-07-16 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 152,472 | US$8.93 | US$136.16万 | 16,970,045 | SEC |
| 2026-07-16 2026-07-20 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 152,472 | US$8.93 | US$136.16万 | 16,970,045 | SEC |
| 2026-07-16 2026-07-20 | ADPT Adaptive Biotechnologies Corp | BOBULSKY SUSAN Officer · Chief Commercial Officer, MRD | 卖出（S） | 5,000 | US$23.00 | US$115,000.00 | 401,288 | SEC |
| 2026-07-15 2026-07-17 | ARQT Arcutis Biotherapeutics, Inc. | Welgus Howard G. Director | 卖出（S） | 4,730 | US$26.91 | US$127,284.30 | 37,109 | SEC |
| 2026-07-15 2026-07-17 | ADPT Adaptive Biotechnologies Corp | LO FRANCIS Officer · Chief People Officer | 卖出（S） | 105,762 | US$22.59 | US$238.92万 | 230,713 | SEC |
| 2026-07-13 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 6,552 | US$8.94 | US$58,574.88 | 16,817,573 | SEC |
| 2026-07-13 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 6,552 | US$8.94 | US$58,574.88 | 16,817,573 | SEC |
| 2026-07-13 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 6,552 | US$8.94 | US$58,574.88 | 16,817,573 | SEC |
| 2026-07-13 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 6,552 | US$8.94 | US$58,574.88 | 16,817,573 | SEC |
| 2026-07-13 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 6,552 | US$8.94 | US$58,574.88 | 16,817,573 | SEC |
| 2026-07-13 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 6,552 | US$8.94 | US$58,574.88 | 16,817,573 | SEC |
| 2026-07-10 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 15,102 | US$8.97 | US$135,464.94 | 16,811,021 | SEC |
| 2026-07-10 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 15,102 | US$8.97 | US$135,464.94 | 16,811,021 | SEC |
| 2026-07-10 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 15,102 | US$8.97 | US$135,464.94 | 16,811,021 | SEC |
| 2026-07-10 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 15,102 | US$8.97 | US$135,464.94 | 16,811,021 | SEC |
| 2026-07-10 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 15,102 | US$8.97 | US$135,464.94 | 16,811,021 | SEC |
| 2026-07-10 2026-07-14 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 15,102 | US$8.97 | US$135,464.94 | 16,811,021 | SEC |
| 2026-07-06 2026-07-08 | PBYI PUMA BIOTECHNOLOGY, INC. | NOUGUES MAXIMO F Officer · Chief Financial Officer | 卖出（S） | 9,386 | US$8.26 | US$77,556.52 | 230,637 | SEC |
| 2026-07-06 2026-07-08 | PBYI PUMA BIOTECHNOLOGY, INC. | HUNT DOUGLAS M Officer · See Remarks | 卖出（S） | 8,460 | US$8.26 | US$69,904.98 | 196,841 | SEC |
| 2026-07-06 2026-07-08 | PBYI PUMA BIOTECHNOLOGY, INC. | AUERBACH ALAN H Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 44,058 | US$8.26 | US$364,051.25 | 7,261,671 | SEC |
| 2026-07-02 2026-07-07 | ADPT Adaptive Biotechnologies Corp | ROBINS HARLAN S Officer · Chief Scientific Officer | 卖出（S） | 239,351 | US$21.74 | US$520.35万 | 1,166,547 | SEC |
| 2026-07-02 2026-07-07 | ADPT Adaptive Biotechnologies Corp | ROBINS HARLAN S Officer · Chief Scientific Officer | 卖出（S） | 146,889 | US$22.45 | US$329.77万 | 1,019,658 | SEC |
| 2026-07-02 2026-07-06 | ADPT Adaptive Biotechnologies Corp | LO FRANCIS Officer · Chief People Officer | 卖出（S） | 44,838 | US$22.59 | US$101.29万 | 230,713 | SEC |
| 2026-07-01 2026-07-06 | ADPT Adaptive Biotechnologies Corp | LO FRANCIS Officer · Chief People Officer | 卖出（S） | 8,743 | US$22.18 | US$193,919.74 | 279,949 | SEC |
| 2026-07-01 2026-07-06 | ADPT Adaptive Biotechnologies Corp | LO FRANCIS Officer · Chief People Officer | 卖出（S） | 42,261 | US$22.50 | US$950,872.50 | 237,688 | SEC |
| 2026-07-01 2026-07-06 | ADPT Adaptive Biotechnologies Corp | BOBULSKY SUSAN Officer · Chief Commercial Officer, MRD | 卖出（S） | 487 | US$22.00 | US$10,714.00 | 406,288 | SEC |
| 2026-06-30 2026-07-02 | LEGN Legend Biotech Corp | Casey Patrick John Director | 卖出（S） | 6,000 | US$14.80 | US$88,800.00 | 48,604 | SEC |
| 2026-06-29 2026-06-30 | ADPT Adaptive Biotechnologies Corp | BENZENO SHARON Officer · Chief Commercial Ofc Imm Med | 卖出（S） | 154,768 | US$21.14 | US$327.18万 | 221,278 | SEC |
| 2026-06-26 2026-07-02 | BNR Burning Rock Biotech Ltd | Han Yusheng Director | 买入（P） | 24,900 | US$8.00 | US$199,090.44 | 18,404,086 | SEC |
| 2026-06-26 2026-06-30 | ADPT Adaptive Biotechnologies Corp | BENZENO SHARON Officer · Chief Commercial Ofc Imm Med | 卖出（S） | 11,034 | US$21.00 | US$231,714.00 | 272,751 | SEC |
| 2026-06-26 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 1,876 | US$8.98 | US$16,846.48 | 16,795,919 | SEC |
| 2026-06-26 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 1,876 | US$8.98 | US$16,846.48 | 16,795,919 | SEC |
| 2026-06-26 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 1,876 | US$8.98 | US$16,846.48 | 16,795,919 | SEC |
| 2026-06-26 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 1,876 | US$8.98 | US$16,846.48 | 16,795,919 | SEC |
| 2026-06-26 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 1,876 | US$8.98 | US$16,846.48 | 16,795,919 | SEC |
| 2026-06-26 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 1,876 | US$8.98 | US$16,846.48 | 16,795,919 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | BIOTECHNOLOGY VALUE FUND II LP Director,Other | 卖出（S） | 837,914 | US$106.50 | US$8923.78万 | 1,960,881 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | BIOTECHNOLOGY VALUE FUND L P Director,Other | 卖出（S） | 837,914 | US$106.50 | US$8923.78万 | 1,960,881 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | Biotechnology Value Trading Fund OS LP Director,Other | 卖出（S） | 837,914 | US$106.50 | US$8923.78万 | 1,960,881 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | BIOTECHNOLOGY VALUE FUND II LP Director,Other | 卖出（S） | 51,858 | US$106.50 | US$552.29万 | 78,787 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | BIOTECHNOLOGY VALUE FUND L P Director,Other | 卖出（S） | 51,858 | US$106.50 | US$552.29万 | 78,787 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | Biotechnology Value Trading Fund OS LP Director,Other | 卖出（S） | 51,858 | US$106.50 | US$552.29万 | 78,787 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | BIOTECHNOLOGY VALUE FUND II LP Director,Other | 卖出（S） | 113,289 | US$106.50 | US$1206.53万 | 240,123 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | BIOTECHNOLOGY VALUE FUND L P Director,Other | 卖出（S） | 113,289 | US$106.50 | US$1206.53万 | 240,123 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | Biotechnology Value Trading Fund OS LP Director,Other | 卖出（S） | 113,289 | US$106.50 | US$1206.53万 | 240,123 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | BIOTECHNOLOGY VALUE FUND II LP Director,Other | 卖出（S） | 627,597 | US$106.50 | US$6683.91万 | 1,592,261 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | BIOTECHNOLOGY VALUE FUND L P Director,Other | 卖出（S） | 627,597 | US$106.50 | US$6683.91万 | 1,592,261 | SEC |
| 2026-06-26 2026-06-26 | KYMR Kymera Therapeutics, Inc. | Biotechnology Value Trading Fund OS LP Director,Other | 卖出（S） | 627,597 | US$106.50 | US$6683.91万 | 1,592,261 | SEC |
| 2026-06-25 2026-06-29 | ADPT Adaptive Biotechnologies Corp | GRIFFIN MICHELLE RENEE Director | 卖出（S） | 52,084 | US$20.18 | US$105.11万 | 15,625 | SEC |
| 2026-06-25 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 31,000 | US$8.88 | US$275,280.00 | 16,794,043 | SEC |
| 2026-06-25 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 31,000 | US$8.88 | US$275,280.00 | 16,794,043 | SEC |
| 2026-06-25 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 31,000 | US$8.88 | US$275,280.00 | 16,794,043 | SEC |
| 2026-06-25 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 31,000 | US$8.88 | US$275,280.00 | 16,794,043 | SEC |
| 2026-06-25 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 31,000 | US$8.88 | US$275,280.00 | 16,794,043 | SEC |
| 2026-06-25 2026-06-29 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 31,000 | US$8.88 | US$275,280.00 | 16,794,043 | SEC |
| 2026-06-25 2026-06-29 | ADPT Adaptive Biotechnologies Corp | BOBULSKY SUSAN Officer · Chief Commercial Officer, MRD | 卖出（S） | 5,000 | US$20.50 | US$102,500.00 | 406,775 | SEC |
| 2026-06-25 2026-06-29 | LEGN Legend Biotech Corp | Huang Ying Director,Officer · Chief Executive Officer | 卖出（S） | 5,566 | US$14.78 | US$82,265.48 | 241,872 | SEC |
| 2026-06-25 2026-06-26 | KRYS Krystal Biotech, Inc. | Thomas John Charles Officer · EVP, General Counsel | 卖出（S） | 1,000 | US$347.27 | US$347,270.00 | 0 | SEC |
| 2026-06-24 2026-07-02 | BNR Burning Rock Biotech Ltd | Han Yusheng Director | 买入（P） | 250,000 | US$8.00 | US$200万 | 18,379,186 | SEC |
| 2026-06-23 2026-07-02 | BNR Burning Rock Biotech Ltd | Han Yusheng Director | 买入（P） | 5,990 | US$7.50 | US$44,920.21 | 18,129,186 | SEC |
| 2026-06-22 2026-07-02 | BNR Burning Rock Biotech Ltd | Han Yusheng Director | 买入（P） | 104,650 | US$7.45 | US$779,673.90 | 18,123,196 | SEC |
| 2026-06-17 2026-06-17 | ARQT Arcutis Biotherapeutics, Inc. | Welgus Howard G. Director | 卖出（S） | 635 | US$25.67 | US$16,300.45 | 37,743 | SEC |
| 2026-06-16 2026-07-02 | BNR Burning Rock Biotech Ltd | Han Yusheng Director | 买入（P） | 111,110 | US$9.00 | US$999,956.67 | 18,018,546 | SEC |
| 2026-06-16 2026-06-17 | ADPT Adaptive Biotechnologies Corp | ROBINS HARLAN S Officer · Chief Scientific Officer | 卖出（S） | 6,160 | US$18.01 | US$110,941.60 | 1,405,898 | SEC |
| 2026-06-16 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 124,893 | US$8.89 | US$111.03万 | 16,763,043 | SEC |
| 2026-06-16 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 124,893 | US$8.89 | US$111.03万 | 16,763,043 | SEC |
| 2026-06-16 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 124,893 | US$8.89 | US$111.03万 | 16,763,043 | SEC |
| 2026-06-16 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 124,893 | US$8.89 | US$111.03万 | 16,763,043 | SEC |
| 2026-06-16 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 124,893 | US$8.89 | US$111.03万 | 16,763,043 | SEC |
| 2026-06-16 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 124,893 | US$8.89 | US$111.03万 | 16,763,043 | SEC |
| 2026-06-15 2026-06-17 | ARQT Arcutis Biotherapeutics, Inc. | Welgus Howard G. Director | 卖出（S） | 4,096 | US$24.41 | US$99,983.36 | 38,378 | SEC |
| 2026-06-15 2026-06-17 | ARQT Arcutis Biotherapeutics, Inc. | LIN SUE-JEAN Director | 卖出（S） | 4,946 | US$24.38 | US$120,583.48 | 27,567 | SEC |
| 2026-06-15 2026-06-17 | ADPT Adaptive Biotechnologies Corp | ROBINS HARLAN S Officer · Chief Scientific Officer | 卖出（S） | 100,000 | US$17.37 | US$173.7万 | 1,412,058 | SEC |
| 2026-06-15 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 15,414 | US$8.99 | US$138,571.86 | 16,638,150 | SEC |
| 2026-06-15 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 15,414 | US$8.99 | US$138,571.86 | 16,638,150 | SEC |
| 2026-06-15 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 15,414 | US$8.99 | US$138,571.86 | 16,638,150 | SEC |
| 2026-06-15 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 15,414 | US$8.99 | US$138,571.86 | 16,638,150 | SEC |
| 2026-06-15 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 15,414 | US$8.99 | US$138,571.86 | 16,638,150 | SEC |
| 2026-06-15 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 15,414 | US$8.99 | US$138,571.86 | 16,638,150 | SEC |
| 2026-06-12 2026-07-02 | BNR Burning Rock Biotech Ltd | Han Yusheng Director | 买入（P） | 210,000 | US$9.25 | US$194.21万 | 17,907,436 | SEC |
| 2026-06-12 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 391,019 | US$8.57 | US$335.1万 | 16,622,736 | SEC |
| 2026-06-12 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 391,019 | US$8.57 | US$335.1万 | 16,622,736 | SEC |
| 2026-06-12 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 391,019 | US$8.57 | US$335.1万 | 16,622,736 | SEC |
| 2026-06-12 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 391,019 | US$8.57 | US$335.1万 | 16,622,736 | SEC |
| 2026-06-12 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 391,019 | US$8.57 | US$335.1万 | 16,622,736 | SEC |
| 2026-06-12 2026-06-16 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 391,019 | US$8.57 | US$335.1万 | 16,622,736 | SEC |
| 2026-06-12 2026-06-15 | PBYI PUMA BIOTECHNOLOGY, INC. | Dorval Allison Director | 卖出（S） | 11,610 | US$7.20 | US$83,592.00 | 90,780 | SEC |
| 2026-06-12 2026-06-15 | PBYI PUMA BIOTECHNOLOGY, INC. | MOYES JAY M Director | 卖出（S） | 22,000 | US$7.22 | US$158,840.00 | 58,322 | SEC |
| 2026-06-12 2026-06-15 | PBYI PUMA BIOTECHNOLOGY, INC. | Senderowicz Adrian Director | 卖出（S） | 27,000 | US$7.20 | US$194,400.00 | 27,000 | SEC |
| 2026-06-12 2026-06-15 | PBYI PUMA BIOTECHNOLOGY, INC. | Stuglik Brian M Director | 卖出（S） | 8,100 | US$7.20 | US$58,320.00 | 113,858 | SEC |
| 2026-06-12 2026-06-15 | PBYI PUMA BIOTECHNOLOGY, INC. | WILSON TROY EDWARD Director | 卖出（S） | 10,800 | US$7.20 | US$77,760.00 | 59,750 | SEC |
| 2026-06-11 2026-07-02 | BNR Burning Rock Biotech Ltd | Han Yusheng Director | 买入（P） | 24,760 | US$8.74 | US$216,387.54 | 17,697,436 | SEC |
| 2026-06-11 2026-06-15 | ADPT Adaptive Biotechnologies Corp | BOBULSKY SUSAN Officer · Chief Commercial Officer, MRD | 卖出（S） | 5,000 | US$19.00 | US$95,000.00 | 411,775 | SEC |
| 2026-06-11 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 548,580 | US$7.91 | US$433.93万 | 16,231,717 | SEC |
| 2026-06-11 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 548,580 | US$7.91 | US$433.93万 | 16,231,717 | SEC |
| 2026-06-11 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 548,580 | US$7.91 | US$433.93万 | 16,231,717 | SEC |
| 2026-06-11 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 548,580 | US$7.91 | US$433.93万 | 16,231,717 | SEC |
| 2026-06-11 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 548,580 | US$7.91 | US$433.93万 | 16,231,717 | SEC |
| 2026-06-11 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 548,580 | US$7.91 | US$433.93万 | 16,231,717 | SEC |
| 2026-06-10 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 103 | US$7.00 | US$721.00 | 15,683,137 | SEC |
| 2026-06-10 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 103 | US$7.00 | US$721.00 | 15,683,137 | SEC |
| 2026-06-10 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 103 | US$7.00 | US$721.00 | 15,683,137 | SEC |
| 2026-06-10 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 103 | US$7.00 | US$721.00 | 15,683,137 | SEC |
| 2026-06-10 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 103 | US$7.00 | US$721.00 | 15,683,137 | SEC |
| 2026-06-10 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 103 | US$7.00 | US$721.00 | 15,683,137 | SEC |
| 2026-06-09 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund, L.P. Director | 买入（P） | 479,039 | US$6.91 | US$331.02万 | 15,683,034 | SEC |
| 2026-06-09 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Healthcare Fund LP Director,TenPercentOwner | 买入（P） | 479,039 | US$6.91 | US$331.02万 | 15,683,034 | SEC |
| 2026-06-09 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | Shah Rajeev M. Director,TenPercentOwner | 买入（P） | 479,039 | US$6.91 | US$331.02万 | 15,683,034 | SEC |
| 2026-06-09 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. Director,TenPercentOwner | 买入（P） | 479,039 | US$6.91 | US$331.02万 | 15,683,034 | SEC |
| 2026-06-09 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | RA Capital Nexus Fund III, L.P. Director | 买入（P） | 479,039 | US$6.91 | US$331.02万 | 15,683,034 | SEC |
| 2026-06-09 2026-06-11 | ARTV Artiva Biotherapeutics, Inc. | Kolchinsky Peter Director,TenPercentOwner | 买入（P） | 479,039 | US$6.91 | US$331.02万 | 15,683,034 | SEC |
| 2026-06-04 2026-06-08 | ADPT Adaptive Biotechnologies Corp | LO FRANCIS Officer · Chief People Officer | 卖出（S） | 39,741 | US$17.49 | US$695,070.09 | 250,934 | SEC |
| 2026-06-04 2026-06-08 | ADPT Adaptive Biotechnologies Corp | BOBULSKY SUSAN Officer · Chief Commercial Officer, MRD | 卖出（S） | 11,000 | US$18.00 | US$198,000.00 | 416,775 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 320 | US$300.75 | US$96,240.00 | 1,474,933 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 640 | US$302.24 | US$193,433.60 | 1,474,293 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 176 | US$303.17 | US$53,357.92 | 1,474,117 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 40 | US$312.23 | US$12,489.20 | 1,450,253 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 964 | US$311.36 | US$300,151.04 | 1,450,293 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 2,652 | US$310.43 | US$823,260.36 | 1,451,257 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 2,784 | US$309.49 | US$861,620.16 | 1,453,909 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 4,830 | US$308.47 | US$148.99万 | 1,456,693 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 544 | US$304.81 | US$165,816.64 | 1,473,573 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 589 | US$306.33 | US$180,428.37 | 1,472,984 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Krish S Director,Officer,TenPercentOwner · President and CEO | 卖出（S） | 11,461 | US$307.68 | US$352.63万 | 1,461,523 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 320 | US$300.75 | US$96,240.00 | 1,402,835 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 593 | US$302.25 | US$179,234.25 | 1,402,242 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 247 | US$303.17 | US$74,882.99 | 1,401,995 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 400 | US$304.89 | US$121,956.00 | 1,401,595 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 480 | US$305.87 | US$146,817.60 | 1,401,115 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 240 | US$311.65 | US$74,796.00 | 1,378,155 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 12,729 | US$307.81 | US$391.81万 | 1,387,038 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 3,803 | US$308.89 | US$117.47万 | 1,383,235 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 2,801 | US$309.95 | US$868,169.95 | 1,380,434 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 2,039 | US$310.94 | US$634,006.66 | 1,378,395 | SEC |
| 2026-06-04 2026-06-05 | KRYS Krystal Biotech, Inc. | Krishnan Suma Director,Officer,TenPercentOwner · President, R&D | 卖出（S） | 1,348 | US$307.09 | US$413,957.32 | 1,399,767 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | AH Bio Fund II, L.P. TenPercentOwner | 卖出（S） | 4,615,974 | US$2.35 | US$1084.75万 | 11,682,032 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | HOROWITZ BENJAMIN A TenPercentOwner | 卖出（S） | 4,615,974 | US$2.35 | US$1084.75万 | 11,682,032 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | AH Equity Partners LSV II, L.L.C. TenPercentOwner | 卖出（S） | 4,615,974 | US$2.35 | US$1084.75万 | 11,682,032 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | Andreessen Horowitz LSV Fund II, L.P. TenPercentOwner | 卖出（S） | 4,615,974 | US$2.35 | US$1084.75万 | 11,682,032 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | Andreessen Marc L TenPercentOwner | 卖出（S） | 4,615,974 | US$2.35 | US$1084.75万 | 11,682,032 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | AH Equity Partners Bio II, L.L.C. TenPercentOwner | 卖出（S） | 4,615,974 | US$2.35 | US$1084.75万 | 11,682,032 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | AH Bio Fund II, L.P. TenPercentOwner | 卖出（S） | 384,026 | US$2.35 | US$902,461.10 | 971,885 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | HOROWITZ BENJAMIN A TenPercentOwner | 卖出（S） | 384,026 | US$2.35 | US$902,461.10 | 971,885 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | AH Equity Partners LSV II, L.L.C. TenPercentOwner | 卖出（S） | 384,026 | US$2.35 | US$902,461.10 | 971,885 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | Andreessen Horowitz LSV Fund II, L.P. TenPercentOwner | 卖出（S） | 384,026 | US$2.35 | US$902,461.10 | 971,885 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | Andreessen Marc L TenPercentOwner | 卖出（S） | 384,026 | US$2.35 | US$902,461.10 | 971,885 | SEC |
| 2026-06-02 2026-06-04 | NAUT Nautilus Biotechnology, Inc. | AH Equity Partners Bio II, L.L.C. TenPercentOwner | 卖出（S） | 384,026 | US$2.35 | US$902,461.10 | 971,885 | SEC |
| 2026-06-01 2026-06-02 | VIR Vir Biotechnology, Inc. | Sabatini Brent Officer · SVP, Chief Accounting Officer | 卖出（S） | 379 | US$9.45 | US$3,581.55 | 61,902 | SEC |
| 2026-06-01 2026-06-02 | VIR Vir Biotechnology, Inc. | Napolitano Janet Director | 卖出（S） | 3,200 | US$9.45 | US$30,240.00 | 21,216 | SEC |
| 2026-06-01 2026-06-02 | MAIA MAIA Biotechnology, Inc. | Gryaznov Sergei Officer · Chief Scientific Officer | 买入（P） | 2,000 | US$1.35 | US$2,700.00 | 46,511 | SEC |
| 2026-06-01 2026-06-02 | MAIA MAIA Biotechnology, Inc. | Smith Stan Director | 买入（P） | 75,000 | US$1.34 | US$100,500.00 | 1,519,178 | SEC |
| 2026-06-01 2026-06-02 | MAIA MAIA Biotechnology, Inc. | Vitoc Vlad Director,Officer,TenPercentOwner · Chief Executive Officer | 买入（P） | 72,700 | US$1.39 | US$101,053.00 | 976,121 | SEC |
| 代码 | 卖空成交量 | 豁免卖空量 | 场外总成交量 | 卖空量占比 | 报告设施 |
|---|---|---|---|---|---|
| BIOT | 147,341 | 35,202 | 512,850.8407 | 28.73% | B, Q, N |
| BIOTW | 2,730 | 430 | 105,497 | 2.59% | Q |